Successful treatment of adult-onset nesidioblastosis by continuous subcutaneous octreotide infusion in a patient on hemodialysis
- PMID: 33489173
- PMCID: PMC7813030
- DOI: 10.1002/ccr3.3514
Successful treatment of adult-onset nesidioblastosis by continuous subcutaneous octreotide infusion in a patient on hemodialysis
Abstract
Octreotide may be useful in noninsulinoma pancreatogenous hypoglycemia syndrome with nesidioblastosis patients who was on hemodialysis. Continuous octreotide subcutaneous infusion can reduce side-effects and stabilize plasma glucose levels.
Keywords: hemodialysis; nesidioblastosis; octreotide.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
None of the authors have any potential conflicts of interest with this report.
Figures
), 75 µg/d ((
), and 100 µg/d ((
)
References
-
- Dravecka I, Lazurova I. Nesidioblastosis in adults. Minireview. Neoplasma. 2014;61:252‐256. - PubMed
-
- Abe M, Kaizu K, Matsumoto K. Plasma insulin is removed by hemodialysis: evaluation of the relation between plasma insulin and glucose by using a dialysate with or without glucose. Ther Apher Dial. 2007;11:280‐287. - PubMed
-
- Witteles RM, Straus FH, Sugg SL, et al. Adult‐onset nesidioblastosis causing hypoglycemia. Arch Surg. 2001;136:656‐663. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
